Neurizon Advances ALS Drug with Positive Survival Data and EMA Orphan Status

• Positive 8-month interim results from NUZ-001 Open-Label Extension study showing doubled survival in ALS patients
• Orphan Medicinal Product Designation granted by EMA, complementing US FDA orphan status
• IND submission for NUZ-001 to support inclusion in HEALEY ALS Platform Trial, currently on FDA clinical hold
• Raised $885,000 via Tranche 2 Placement Shares to related parties following shareholder approval